Dear Editor-in-Chief
====================

Testicular cancer (TC) remains as a relatively infrequent tumor type, considered about 1% of all men cancers worldwide ([@B1]). In the recent years, the incidence of TC has a growing trend, so in many western societies, the incidence of TC is about doubling detected since the 1960s. In 2012, maximum and minimum of Age-Standardized Incidence Rates (ASIR) of TC in the world, observed in western Europe (ASIR=8.7 per 100000) and in Africa (ASIR= 0.4 per 100000), respectively ([@B2]). TC may seem at every age group but tend to happen in three separate age groups: 0 to 10 yr (infants and children), 15 to 40 yr (young adults) and over 60 yr (older adults) ([@B3], [@B4]). This tumor develops rapidly, so in 20 to 30 d tumor size is doubled and has a great risk of metastatic extent ([@B5]). Nonetheless, when it is detected and treated in early stages of disease, TC is treatable, so in developed countries, five years survival rate of disease is over 95% ([@B6]). However, survival rate of TC in developing countries is low, therefore, in the study that conducted in Tanzania, five years survival rate of TC was 22.2% ([@B7]).

In GLOBOCAN project, the estimated number of new cases and deaths of TC in a region or country in 2015, 2020, 2025, 2030 and 2035 is calculated by multiplying the age-specific rates estimated for 2012, by the corresponding expected population for 2015, 2020, 2025, 2030 and 2035. Based on GLOBOCAN project in the world in 2012, the number of 55266 new cases of TC was observed that among them 52305 cases (94.64%) were in the age group below 65 yr and 2961 cases (05.35%) were in the age group 65 yr and older. Moreover, in this year, the number of 10351 cases of death were observed that among them 7790 cases (75.25%) were in the age group below 65 yr and 2561 cases (24.75%) were in the age group 65 yr and older. According to the predictions in the years 2015, 2020, 2025, 2030 and 2035, the number of new cases of TC in the world respectively is equal to 57209, 60007, 62903, 65827 and 68351 cases. Besides, the number of deaths of TC respectively be equal to10904, 11790, 12781, 13847 and 14886 ([Table 1](#T1){ref-type="table"}).

###### 

Predict the number of incidence and mortality of testis cancer in the world from 2012--2035

  ***Year***   ***Predict number of new cases and deaths of TC***   ***Demographic change***                                                                     
  ------------ ---------------------------------------------------- -------------------------- ------ ------ ------- ------- ------ ------ ------ ------ ------- ------
  2012         52305                                                7790                       2961   2561   55266   10351   R      R      R      R      R       R
  2015         53958                                                8097                       3251   2807   57209   10904   1653   307    290    246    1943    553
  2020         56169                                                8491                       3838   3299   60007   11790   3864   701    877    738    4741    1439
  2025         58384                                                8887                       4519   3894   62903   12781   6079   1097   1558   1333   7637    2430
  2030         60490                                                9233                       5337   4614   65827   13847   8185   1443   2376   2053   10561   3496
  2035         62160                                                9522                       6191   5364   68351   14886   9855   1732   3230   2803   13085   4535

Population forecasts were extracted from the United Nations, World Population Prospects, the 2012 revision. Numbers are computed using age-specific rates and corresponding populations for 10 age-groups. GLOBOCAN 2012 (IARC) - 15.3.2016. Demographic changes were computed for years 2015--2035, based on the number of TC in the World in 2012 as a Reference group(R)

However, the number of incidence and mortality of TC will be increasing trend, but this increase will be more in the age group 65 yr and older. Thus, diagnosis and treatment of patients with TC in the early stages of disease lead to improving the quality of life and survival rate of patients.
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